Top Health Tech Companies in NYC, NY (1,177)

Strong Revenue Growth: Revenue is reported to have grown at a robust compound rate over multiple years, with momentum described as accelerating as of 2026. Company updates and industry reporting consistently point to ongoing top-line expansion alongside network scale-up.

Profitability: The company indicates it has been annually profitable since 2023 and cash-flow positive, and it cites performance above the 'Rule of 40' benchmark in 2025. This signals growth paired with financial discipline rather than expansion funded by sustained losses.

Strategic Partnerships: The Care Access Network extends booking into platforms including Amazon Health AI, Google Gemini, Yelp, Healthgrades, and Blue Shield of California. Partner implementations are described as materially increasing booked appointments and expanding available bookable hours, indicating traction beyond the core site.

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Market Expansion: Operations span all 50 states and Washington, D.C., with coverage reported across 100+ health plans and expansion into Medicare Advantage and Medicaid. This broadened payer and geographic footprint increases addressable demand and distribution leverage.

Product Line Growth: Offerings have expanded beyond matching into EHR, AI‑assisted notes, telehealth, billing, integrated‑care referrals, and a patient app. These additions deepen provider engagement and create more touchpoints for utilization and scale.

Strong Revenue Growth: Annual revenue is described as having more than doubled over a recent 12‑month period in 2024, indicating accelerating commercial momentum. While later‑period figures are not disclosed, the earlier surge aligns with rapid operating scale increases.

Strong Revenue Growth: Feedback suggests AKASA reports more than tenfold growth since mid-2024 and nearly sixfold year-over-year inpatient volume processed, indicating rapid commercial traction and usage expansion.

Market Expansion: Feedback suggests deployments have broadened across major U.S. health systems, with a footprint reportedly spanning roughly 500 hospitals and customers representing about 10% of U.S. inpatient discharges.

Investor Backing & Capital Strength: Feedback suggests AKASA has attracted substantial capital, with reported total funding around $200M+, providing resources to scale products and partnerships.

Strong Revenue Growth: Reported ARR surpassed $200 million in June 2026 with five consecutive years of 100% year-over-year growth, indicating rapid scaling. Adoption breadth, including claims of powering one in six U.S. apartments, reinforces the commercial momentum behind that trajectory.

Investor Backing & Capital Strength: A $350 million round in September 2026 at a $4 billion valuation, with major existing investors participating alongside Ontario Teachers’ Pension Plan, underscores substantial access to capital. This financing signals strong confidence to fund continued product development and go-to-market expansion.

Market Expansion: Reach reportedly grew from about one in twelve U.S. apartments in 2024 to one in six in 2026, alongside plans for a second engineering hub in San Francisco. The company is also expanding from leasing into broader property-management workflows and healthcare administration.

Investor Backing & Capital Strength: A $30 million Series B led by Andreessen Horowitz in February 2025 brought total funding to $50 million, with Axios independently reporting the round. This capital base supports continued hiring and expansion across product and go-to-market functions.

Market Expansion: The company reports expanding from behavioral health/ABA into physical therapy, ENT/allergy, and broader specialty care, and now serves 500+ providers across all 50 states. Year-end 2025 metrics also cite 81.8% growth in clinics and 163% growth in patients, and a 2026 acquisition added workflow automation expertise.

Innovation-Driven Growth: Platform capabilities are built on more than $2.5 billion in claims data with millions of claims processed, and reported a 12.3% year-over-year improvement in first-pass paid rate. These data- and automation-led workflows underpin scaling of claims across a nationwide footprint.

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Market Expansion: Customer adoption is portrayed as rising from 18,000+ veterinary hospitals in 2022 to 23,000+ by 2024, with a later 25,000+ milestone cited in 2026 across all 50 states. These published milestones indicate broader reach and usage over time, even if exact annual growth rates are not verified.

Strong Hiring & Retention: Workforce estimates point to organizational expansion from 204 employees in 2023 to 343 in early 2026, with ongoing openings across engineering, product, data, and commercial roles. This pattern suggests the company is scaling capacity to support a larger customer base.

Strategic Partnerships: Integrations and industry ties have broadened, including IDEXX Neo, Digitail, DaySmart Vet, and AVMA Direct Connect, alongside other association relationships. These connections embed the platform in day‑to‑day clinic workflows and extend distribution channels.

Strong Revenue Growth: Feedback suggests revenue expanded rapidly, highlighted by a first-place ranking in the FT’s 2026 Americas’ Fastest-Growing Companies based on 2021–2024 growth and a reported $617.4M in 2024 revenue. Additional signals include reported surges in appointments and broader commercial activity across 2025–2026.

Investor Backing & Capital Strength: Feedback suggests substantial access to capital, including a $150M Series D in March 2026 and cumulative funding of about $328M. This capital appears to support expansion into insurers, employers, and health-system partnerships.

Market Expansion: Feedback suggests the company expanded distribution via 125+ health-plan partners (later 135), employer benefits, and health-system integrations. These channels appear to broaden reach beyond direct patient acquisition.

Strong Revenue Growth: Reported subscription revenue nearly quadrupled from $8M to $29M while contracted revenue surpassed $60M. These figures indicate accelerating monetization tied to expanding deployments.

Investor Backing & Capital Strength: A $70M Series C in September 2026 brought total funding to $225M alongside a valuation above $500M. This level of committed capital suggests substantial capacity to scale sales, hardware, and AI development.

Market Expansion: Technology is deployed across 500+ senior-living communities and monitors roughly 40,000 residents, with stated plans to expand go-to-market efforts. Adoption across major senior-housing investors and operators points to a broadening commercial footprint.

Strong Revenue Growth: Historical revenue acceleration is underscored by a top-50 placement on the 2026 Inc. 5000 and reported 2025 profitability, pointing to substantial commercial momentum.

Investor Backing & Capital Strength: Successive venture rounds culminating in a $100 million Series C and approximately $215 million total funding indicate deep capital support for expansion into AI, provider capacity, and broader metabolic care.

Market Expansion: Reported nationwide availability includes access to over 200 million covered lives, a network exceeding 10,000 registered dietitians, and more than 500,000 patients served, signaling rapid scaling of distribution and capacity.

Strong Revenue Growth: Revenue is reported to have nearly doubled during CEO Carolyn Starrett’s tenure beginning in 2021, alongside expansion of the real‑world data platform and commercial evidence services. This is the clearest direct indicator of commercial momentum even though underlying figures were not disclosed.

Market Expansion: International oncology research reach expanded markedly, with the network tripling in 2025 and then growing nearly 70% year over year by July 2026 to more than 50 sites across the UK, Germany and Japan, including a first partnership in Scotland. This points to broader geographic access and commercial reach.

Product Line Growth: Data assets and offerings have broadened, with the evidence base growing to more than six million patient records and launches such as the AI-enabled Telescope platform and expanded Panoramic datasets. These developments indicate deeper research utility and a wider product portfolio.

Strong Revenue Growth: Company disclosures point to multi‑year top‑line expansion, with independent credit commentary anticipating continued gains. The scale of the installed healthcare network reinforces commercial traction over time.

Market Expansion: Recent launches of a Consumer Health Network and programmatic advertising capabilities extend reach beyond traditional pharmaceutical clients and open new buying channels. These moves indicate active growth into adjacent advertiser categories within healthcare settings.

Investor Backing & Capital Strength: A definitive agreement to be acquired by a global private‑equity firm underscores institutional confidence and adds resources to accelerate network growth and product innovation. The transaction highlights access to capital to support scaling.

Market Expansion: Broker and enrollment expansion is evident, with the network reported at 10,000+ brokers and approximately 250,000 enrollments in 2025, up sharply from early-2024 levels. Updates in 2026 describe adding 3,000 brokers and surpassing the prior year’s enrollment total within seven months.

Investor Backing & Capital Strength: Capital access is reinforced by a $25 million Series B in January 2024, described as a fourfold valuation step-up versus the prior round. Independent profiles also reference substantial total funding, supporting capacity to invest in product and operations.

Customer Loyalty & Retention: Client stickiness is highlighted by an average 84% retention rate after partnering. Reported partner production gains further suggest sustained engagement with Spark’s platform.

Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.

Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.

Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Investor Backing & Capital Strength: A $50 million financing package in April 2025—described as oversubscribed and comprising $30 million in equity and $20 million in credit—signals strong access to capital for scaling. This followed a $32 million Series A in 2024, indicating continued investor support.

Strategic Partnerships: Partnerships announced in 2026 with PrismHR and entry into the Workday Wellness Program extend distribution through established HR ecosystems, creating access to broad employer networks. These relationships add go-to-market channels beyond direct sales.

Innovation-Driven Growth: New offerings in 2025–2026—such as AI-powered claims analytics, Zoe for HR, and a cash-pay care network—indicate active product expansion. Integrations that bring Zoe to Slack and Microsoft Teams further broaden usage contexts and signal ongoing investment in product breadth.

Product Line Growth: Newer and acquired medicines grew 18% operationally in Q2 2026, while revenue excluding Comirnaty and Paxlovid rose 5% operationally in the same period. Excluding COVID products, 2025 revenue also increased 6% operationally, supported by growth in products such as Eliquis and Padcev.

Cost & Operational Efficiency: Management is pursuing additional savings to improve operational efficiency and support profitability. These cost-control efforts are intended to help the business transition away from pandemic-driven sales while supporting margins.

Innovation-Driven Growth: Investment in future growth includes $10.4 billion in internal R&D during 2025 and ongoing development in oncology and obesity. A broad pipeline and recent acquisitions are intended to offset declining COVID-19 sales and patent expirations if programs succeed.

Product Line Growth: Flume now markets a secure AI platform for healthcare data, claims analysis, payment integrity, dashboards, and automation, indicating an expanded use-case portfolio. Its website presents case studies involving health plans, TPAs, and payers, supporting evidence of active product development.

Market Expansion: Current materials show the company targeting health plans, third-party administrators, providers, and consulting firms rather than only employer plan administration. This broader positioning suggests efforts to reach multiple market segments, though it does not by itself confirm revenue growth.

Investor Backing & Capital Strength: A $30 million Series A in 2022, bringing total funding to roughly $40 million with investors including Optum Ventures and Cigna Ventures, demonstrates meaningful historical capital support. While dated, this financing helped fund product development and repositioning.

Strong Hiring & Retention: Headcount and hiring momentum are evident, with third-party estimates showing growth from roughly the mid‑teens of thousands in 2024 to 20,000+ by 2025–2026 and plans to hire thousands, alongside new capacity such as the Hyderabad operations center. This suggests the company is scaling delivery and talent depth across geographies.

Innovation-Driven Growth: The firm has expanded into AI and digital offerings, including its ZAIDYN platform, acquisitions like Digital Additive and Torrent Consulting, and launches such as Myelo developed with the International Myeloma Foundation. These moves indicate investment beyond traditional consulting into scalable, tech‑enabled services.

Market Expansion: A dedicated mid‑cap pharmaceutical vertical and the opening of an operations center in Hyderabad point to deliberate expansion in target segments and delivery footprint. These steps signal efforts to broaden served markets and strengthen execution capacity.